Jaume Capdevila News Today

Investegate announcements from ITM Isotope Technologies Munic, ITM to Present Phase III COMPOSE Poster and Host Satellite Symposium on Radiotheranostics in NET cancer at ENETS Conference

Garching / Munich, March 16, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical theranostics company, today announced that the...

Garching / Munich, March 16, 2023 - ITM Isotope Technologies Munich SE) in a poster presentation at the 20th Annual European Neuroendocrine Tumor Society(n.c.a. 177Lu-edotreotide) compared to standard

03.05.2022 - Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the European Commission (EC) has approved the use of Cabometyx (cabozantinib) as a monotherapy for the treatment of adult patients with locally advanced or metastatic ... Seite 1

Approval based on data from the COSMIC-311 Phase III trial, in which Cabometyx (cabozantinib) demonstrated a 78% reduction in risk of disease progression or death versus placebo1 This milestone

Approval based on data from the COSMIC-311 Phase III trial, in which Cabometyx® (cabozantinib) demonstrated a 78% reduction in risk of disease progression or death versus placebo1This milestone marks the first treatment option to be specifically approved as a second-line therapy in this indicationDisclaimer: Intende...

Ipsen announces European Commission approval of the use of Cabometyx® (cabozantinib) as a monotherapy for the treatment of adult patients

Recommendation based on data from the COSMIC-311 Phase III trial, in which Cabometyx (cabozantinib) demonstrated a 78% reduction in risk of disease progression or death versus placebo1 Disclaimer:

email article The multitargeted tyrosine kinase inhibitor (TKI) lenvatinib induced a strong tumor response in patients with previously treated advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs), according to results from a phase II trial in Europe. In this multicenter, open-label study involving 111 patients, treatment with lenvatinib (Lenvima) led to an overall response rate (ORR) of 29.9%, with a particularly high ORR -- 44.2% -- in patients with pancreatic NETs, repor...